Evaluation of GSK Biologicals' Boostrix Vaccine When Compared With Decavac in Adults Aged 65 Years or Older.

Trial Profile

Evaluation of GSK Biologicals' Boostrix Vaccine When Compared With Decavac in Adults Aged 65 Years or Older.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Dec 2011 Results published in Vaccine.
    • 09 Jul 2011 Based on the results from this trial, the vaccine was approved by the US FDA for use in subjects aged 65 years or older.
    • 16 Jun 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top